JAGX — Stock Film
STOCK FILMSCENE 1/11JAGX · $1.30
Stock Expert AI presents
JAGX
Jaguar Health, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Jaguar Health, Inc. A quick introduction.

On the stock market since 2015, it operates in the world of health and science. It has 47 employees. Now — the numbers.

on the stock market since 2015
47 employees
$87K market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $6.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
98%Mytesi
Mytesi 98%License 2%Neonorm <1%
98% of all revenue comes from a single line: Mytesi.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $43.6M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
32
very weak

Clearly below the class average.

FINANCIAL STRENGTH
66
strong

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
5
very weak

Clearly below the class average.

GROWTH
40
weak

Clearly below the class average.

PRICE MOMENTUM
6
very weak

Clearly below the class average.

WORTH WATCHING

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
WEAK SPOTS
The stock has lost its spark0/10
Growth has stalled2/10
Heavy bets against the stock3/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Executives are buying their own stock

Over the last 12 months, company executives reported 46 buys and 9 sells. Management buying with its own money is usually read as a good sign.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $3.21147% above today’s price.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $53.6M against $11.5M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, JAGX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: JAGX is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (5/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film